Citryll raises EUR 85 million Series B to advance novel net-targeting therapy for immune-mediated inflammatory disorders
We’re proud to celebrate Citryll’s €85 million Series B financing, led by Johnson & Johnson Innovation JJDC Inc, Forbion, and Novartis Venture Fund, alongside other existing stakeholders.
This funding will accelerate the development of CIT-013, their first-in-class monoclonal antibody targeting Neutrophil Extracellular Traps (NETs), advancing into Phase 2a clinical trials for rheumatoid arthritis and hidradenitis suppurativa.
Congratulations to the Citryll team for this incredible milestone, driving innovation in immune-mediated inflammatory diseases.
For more information click here.
Find more news here.